March 24, 2006
Article
A cautious approach to supplements and a discussion with your physician while taking them during treatment is a must.
FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer
Lunsumio plus Polivy Associated With Responses in MCL
Standing Up to Cancer with Lynch Syndrome
Zidesamtinib Elicits Responses in ROS1-Positive NSCLC